The earnings results for CRISPR Therapeutics (NASDAQ: CRSP) for Q4 were made public on Thursday, February 12, 2026 at 04:00 PM. Here's a comprehensive overview of the announcement. CRISPR Therapeutics ...
CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.
13d
Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Mixed Trading And Discounted P/B Ratio
CRISPR Therapeutics overview after recent trading moves CRISPR Therapeutics (CRSP) has seen mixed trading recently, with the ...
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
What is CRISPR gene editing? CRISPR gene editing technologies enable changes to be made to DNA at specific regions. These changes can involve DNA insertion or deletion, or base pair disruption and can ...
CRISPR is the basis of a revolutionary gene editing system. One day, it could make it possible to do everything from resurrect extinct species to develop cures for chronic disease. It’s built on a ...
Labroots invites you to the 8th Annual CRISPR Virtual Event Series 2025, taking place on October 22nd, 2025! This event will explore the expanding frontier of CRISPR technology, with sessions covering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results